Antinol® Latest Studies
Sorted by recent
Filter Studies by Smart Tags
Bone & JointCardiovascularCase Study & ProceedingCatDogEAB 277™EfficacyExotic PetImmunologyNeuro & BehaviorOphthalmologyOralRabbitRenalRespiratoryRodentSafetySkinUTI
Smart Search
Safety study of polyunsaturated fatty acids extracted from New Zealand green lipped mussel and krill on hematology and blood chemistry profiles of healthy
Authors:
Abstract
New Zealand green-lipped mussel (Perna canaliculus) is a shellfish with a green shell containing many types of fatty acids, especially polyunsaturated fatty acids (PUFAs).
The aim of the present study was to investigate the safety of dietary PUFAs supplementation on blood hematology, chemistry and coagulogram pancreatic enzymes in dogs and cats. Twelve healthy beagle dogs and healthy mature cats were used in these studies. Complete randomized block and triplicate 4×4 Latin square designs were used for these dog and cat safety studies, respectively. Experimental diets composed of sham control (0X) and 3 treatment groups, including 1X, 3X, and 10X of PUFAs capsules containing extracted mussel (60% or 30 mg/capsule) and krill (40% or 20 mg/capsule), were given consecutively for 56 days.
Blood samples were collected every 28 days for hematology, chemistry and coagulogram, and pancreatic enzyme analysis. Hematology and blood chemistry results were in normal ranges and no animals appeared to reveal any abnormal signs.
Dogs fed 3X had significantly (P<0.05) higher in creatine compared to 0X and 1X at D28. Likewise, there were statistically significant differences in the time of cat’s ALT and lipase. Group of cats fed 10X significant reduction in ALT at D56 compared to D0 (P<0.01) and D28 (P<0.05).
In the group of cats fed at 1X, there was a significant within-group difference between the values of ALT levels for baseline (D0) and D56 (P<0.05). At D56, cats in all groups had a significantly higher amount of lipase levels than those at D0 (P<0.05). The prothrombin time of cats in the 0X and 10X groups showed a significant within-group difference between the values for D0 and D56 (P<0.05). PLI of dogs and cats showed good pancreatic function based on precision accuracy.
Overall, EAB-277 contains PUFAs and appears to be safe and improves liver function, especially in cats receiving 10 X administration of EAB-277.
Keywords: blood chemistry, cat, dog, hematology, New Zealand green lipped mussel, PUFA
Evaluation of the comparative efficacy of green lipped mussel plus krill oil extracts (EAB-277), Biota orientalis extracts or NSAIDs for the treatment of dogs with osteoarthritis associated pain: a blinded, placebo-controlled study
With little to no regulation of the supplement markets and a paucity of quality information regarding clinical utility of individual marketed supplements, it is difficult for veterinarians to provide any evidence-based recommendations to owners. The current study aimed to provide clinically useful comparative efficacy data on certain marketed supplements.
Discussion: Results of this study indicate that meloxicam and EAB-277 have significant objectively measured benefits in managing OA-related pain in dogs compared to placebo, but 4CYTE does not differ from placebo.
Antinol® Rapid is a potent synergistic blend of 2 marine lipid extracts chosen for their unique enhancement formula called EAB-277®.
EAB-277® is the key active ingredient of this advanced formula formulated to promote optimal benefits through its synergistic efficacy contains > 90 free fatty acids full spectrum of Omega 3 including ETA, EPA, DHA as well as other key Polyunsaturated fatty acids (PUFAs) and antioxidants.
The two marine lipids used in Antinol® Rapid are proprietary and exclusively produced. The exact combination of 30mg lipid fractions from Perna canaliculus (New Zealand green lipped mussel) and 20mg high phospholipid krill oil is the result of years of research combining and isolating lipid groups and essential fatty acids to find the optimal nutrient synergy.
EAB-277®’s proprietary high phospholipid krill oil is high in polar lipid enrichment which enhances bioactivity “Potency” of this marine oil blend formula as a result of proven efficacy.
The Antinol® Rapid EAB-277® blend has been proven via laboratory tests to be more effective than either of the individual lipids alone in inhibiting inflammation markers such as nitric oxide, TNFα, and IL-6.
Preliminary Study on Treatment Outcomes and Prednisolone Tapering after Marine Lipid Extract EAB-277 Supplementation in Dogs with Immune-Mediated Hemolytic Anemia
Simple Summary: Immune-mediated hemolytic anemia (IMHA) in dogs is a common autoimmune disease which is accompanied with a high death rate and therapeutic challenges. A natural antiinflammatory nutraceutical product, EAB-277, is derived from marine lipids. Unfortunately, the effects of EAB-277 in IMHA dogs has rarely been investigated. The objective of this study is to assess the clinical effects of EAB-277 and prednisolone dose-tapering for supplemental therapy in IMHA dogs. The findings provide evidence that standard therapy combined with EAB-277 can improve hematological and blood chemistry profiles, resulting in a higher survival rate in IMHA dogs. Furthermore, EAB-277 supplementation can reduce prednisolone dosage tapering and improve the quality of life of IMHA dogs. However, a longer-term study with a larger sample size is necessary to corroborate these findings. As a result, marine EAB-277 is a promising alternative to existing medication for IMHA. Since the nutraceuticals have been utilized not only for nutrition but also as supplemental therapy for the treatment of a wide range of illnesses, such as minimizing the adverse effects of immunosuppressive therapy with steroids.
Updated Study Topics
New researches and publications related to PCSO-524® and its result in clnical test submitted by veterinarians on the global conferences every year and the data keeps growing with more studies conducted
